OrbiMed’s Clovis Oncology, Inc. CLVS Stock Holding History

OrbiMed’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,913,234	Closed	-$28.4M	–	149
2019 Q2	$28.4M	Sell	1,913,234 -919,066	-32%	-$16.6M	0.45%	55
2019 Q1	$70.3M	Buy	2,832,300 +80,100	+3%	+$2.01M	1.1%	29
2018 Q4	$49.4M	Buy	2,752,200 +517,630	+23%	+$10.6M	0.92%	37
2018 Q3	$65.6M	Sell	2,234,570 -96,300	-4%	-$3.73M	0.79%	39
2018 Q2	$106M	Hold	2,330,870	–	–	1.27%	26
2018 Q1	$123M	Buy	2,330,870 +359,200	+18%	+$21M	1.54%	19
2017 Q4	$134M	Sell	1,971,670 -417,000	-17%	-$29.2M	1.7%	18
2017 Q3	$197M	Buy	2,388,670 +284,300	+14%	+$22.5M	1.89%	15
2017 Q2	$197M	Buy	+2,104,370	New	+$129M	2.07%	16
2016 Q2	–	Sell	-660,900	Closed	-$12.7M	–	147
2016 Q1	$12.7M	Sell	660,900 -68,700	-9%	-$1.45M	0.13%	80
2015 Q4	$25.5M	Sell	729,600 -376,300	-34%	-$24.3M	0.23%	68
2015 Q3	$102M	Buy	1,105,900 +100,700	+10%	+$8.71M	1.03%	35
2015 Q2	$88.3M	Buy	1,005,200 +4,800	+0.5%	+$411K	0.75%	40
2015 Q1	$74.3M	Buy	1,000,400 +286,300	+40%	+$20.2M	0.65%	45
2014 Q4	$40M	Buy	+714,100	New	+$37.5M	0.39%	56

Other funds holding CLVS

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return